Kitaw Negash, Ph.D is a DMPK scientist with over 30 years of pharmaceutical and research experience. Dr Negash’s expertise include drug metabolism, biotransformation mechanism, identifying and risk mitigation of reactive metabolites, pharmacokinetics, and structure-tissue distribution relationships. Dr Negash joined GlaxoSmithKline as a senior research chemist and have been working for the last 20 years. During these years, he supported drug discovery and development activities for more than 20 small and large molecules.

Before joining GlaxoSmithKline, Dr. Negash worked in American Cyanamid Company (later BASF) in Princeton, NJ for 4 years as a synthetic radiochemist, where he synthesized 14C-labelled compounds for drug metabolism studies and supported metabolism profiling work. Prior to joining American Cyanamid Company, Dr. Negash was a post-doctoral fellow in Lawrence Berkeley National Laboratory at the University of California at Berkeley, where he was involved in the synthesis of F-18 labeled PET radiopharmaceuticals as potential diagnostic tools. Dr. Negash received his Ph.D in Medicinal Chemistry. His dissertation research was focused on the synthesis of conformationally restricted analogues of B-phenyldopamine pharmacophore.